The inhibitory effect of progesterone on lactogenesis during pregnancy is already evident by mid- to late gestation in rodents

Lactogenesis is a very complex process highly dependent on hormonal regulation. In the present study the time-course of the inhibitory actions of progesterone on prolactin secretion, mammary gland morphology and lactogenesis from mid- to late gestation in rodents was investigated. Groups of pregnant rats were luteectomised or administered with mifepristone on Day 10, 13, 15 or 17 of gestation and decapitated 28 or 48h later. Whole-blood samples and the inguinal mammary glands were taken for determinations of hormone levels and for measurement of mammary content of casein and lactose and for tissue morphology analyses, respectively. Luteectomy or mifepristone evoked prolactin increases only after Day 17 of gestation. Mammary content of casein was increased by both treatments regardless of timing or duration. Mifepristone was less effective than luteectomy in inducing lactose production and the effect was only observed after Day 15 of gestation. Analysis of mammary gland morphology confirmed the observed effect of progesterone on lactogenesis. Both treatments triggered remarkable secretory activity in the mammary gland, even without a parallel epithelial proliferation, demonstrating that the mammary epithelium is able to synthesise milk compounds long before its full lobulo-alveolar development is achieved, provided that progesterone action is abolished. Thus, the present study demonstrates that progesterone is a potent hormonal switch for the prolactin and prolactin-like effects on mammary gland development and its milk-synthesising capacity during pregnancy, and that its inhibitory action is already evident by mid-pregnancy in rodents.Fil: López Fontana, Constanza Matilde. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Maselli, María Eugenia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Salicioni, Ana M.. University Of Massachusetts Amherst; Estados UnidosFil: Caron, Ruben Walter. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentin

Serum levels of proinflammatory cytokines in prostate cancer

Prostate cancer has become an important public health problem affecting millions of men worldwide every year. Like other malignant tumors, prostate cancer shows evidence of a strong inflammatory component that is dependent on the release of pro-inflammatory cytokines,which might play a major role in the development and progression of the tumor, helping in its early stage, progression and aggressiveness. Aims: The goal of this study was to determine the relationships between the serum levels of pro-inflammatory cytokines and the different stages of prostate cancer. To this end, sera from patients enrolled by The Laboratory of Metabolic Diseases and Cancer of the Faculty of Pharmacy and Biochemistry at the University Juan Agustín Maza in Argentina, were analyzed through ELISA and their pro-inflammatory cytokines (IL-6, TNF-α and MCP-1) quantified. Patients were first classified into three groups (Control, at Risk, and Cancer subjects) and anthropometric, biochemical and histological parameters of prostate were then determined for all groups. Results and Conclusions: Despite displaying elevated serum concentrations of IL-6 and TNF-α in the Cancer and the Risk groups compared to the Control group, the differences did not reach significance. However, there was a positive correlation between these cytokines only in the Risk and Cancer groups, showing a general inflammatory behavior in these patients. The results obtained provide general data about the behavior of pro-inflammatory cytokines in prostate cancer. However, they do not demonstrate a direct correlation betweenserum levels and neoplastic progression. Nevertheless, these findings do not rule out a possible relationship between prostate cancer and serum levels of pro-inflammatory cytokines.Fil: López Fontana, Constanza Matilde. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Defagó, María Teresa. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; ArgentinaFil: Huilcaman, Ricardo. Universidad de Talca; ChileFil: Lopez, José. Universidad Nacional de Cuyo; ArgentinaFil: Moore Carrasco, Rodrigo. Universidad de Talca; Chile. Universidad de Talca. Programa de Investigación Asociativa en Cáncer Gástrico; Chil

Serum levels of proinflammatory cytokines in prostate cancer

Prostate cancer has become an important public health problem affecting millions of men worldwide every year. Like other malignant tumors, prostate cancer shows evidence of a strong inflammatory component that is dependent on the release of pro-inflammatory cytokines,which might play a major role in the development and progression of the tumor, helping in its early stage, progression and aggressiveness. Aims: The goal of this study was to determine the relationships between the serum levels of pro-inflammatory cytokines and the different stages of prostate cancer. To this end, sera from patients enrolled by The Laboratory of Metabolic Diseases and Cancer of the Faculty of Pharmacy and Biochemistry at the University Juan Agustín Maza in Argentina, were analyzed through ELISA and their pro-inflammatory cytokines (IL-6, TNF-α and MCP-1) quantified. Patients were first classified into three groups (Control, at Risk, and Cancer subjects) and anthropometric, biochemical and histological parameters of prostate were then determined for all groups. Results and Conclusions: Despite displaying elevated serum concentrations of IL-6 and TNF-α in the Cancer and the Risk groups compared to the Control group, the differences did not reach significance. However, there was a positive correlation between these cytokines only in the Risk and Cancer groups, showing a general inflammatory behavior in these patients. The results obtained provide general data about the behavior of pro-inflammatory cytokines in prostate cancer. However, they do not demonstrate a direct correlation betweenserum levels and neoplastic progression. Nevertheless, these findings do not rule out a possible relationship between prostate cancer and serum levels of pro-inflammatory cytokines.Fil: López Fontana, Constanza Matilde. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Defagó, María Teresa. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Córdoba. Instituto de Investigaciones en Ciencias de la Salud. Universidad Nacional de Córdoba. Instituto de Investigaciones en Ciencias de la Salud; ArgentinaFil: Huilcaman, Ricardo. Universidad de Talca; ChileFil: Lopez, José. Universidad Nacional de Cuyo; ArgentinaFil: Moore Carrasco, Rodrigo. Universidad de Talca; Chile. Universidad de Talca. Programa de Investigación Asociativa en Cáncer Gástrico; Chil

High intake of lycopene together with low intake of red meat increases the total antioxidant status

Los sistemas antioxidantes del cuerpo humano son capaces de remover a los radicales libres, protegiendo así al organismo del daño que estos pueden ocasionar, y pueden ser valorados en conjunto mediante la determinación del poder antioxidante total (TAS, por sus siglas en inglés). Este biomarcador es modulado por la alimentación mediante la incorporación de sustancias con propiedades antioxidantes o prooxidantes. El objetivo del presente trabajo fue estimar la ingestión de nutrientes antioxidantes y grupos específicos de alimentos y correlacionarla con el TAS. Fueron seleccionados al azar 45 sujetos de sexo masculino, entre 50 y 75 años, de una consulta médica de rutina. El trabajo consistió en una evaluación de TAS mediante técnica ABTS más una entrevista nutricional donde se evaluó la composición corporal mediante antropometría y la ingestión habitual de nutrientes y grupos específicos de alimentos mediante un recordatorio de 24 h y un cuestionario de frecuencia de consumo de alimentos validado para tal fin. El análisis estadístico se realizó mediante Coeficiente de Correlación de Pearson o Spearman según la normalidad de la muestra (p<0,05). El TAS se correlacionó positivamente con el consumo de licopeno (r=0,333; p=0,027) y negativamente con la ingestión de carnes rojas (r= -0,403; p=0,007). Los demás nutrientes o alimentos no se correlacionaron con el TAS. Por lo tanto, una ingestión elevada de licopeno y un consumo reducido de carnes rojas ayudarían a mejorar el sistema antioxidante del organismo.The body's antioxidant systems are able to remove free radicals, thus protecting the body from the damage they may cause. They can be estimated, as a whole, through the determination of total antioxidant status (TAS). This biomarker can be modulated by dietary factors through the incorporation of substances with antioxidant or prooxidant properties. The aim of this study was to estimate the intake of antioxidant nutrients and specific food groups, and its correlation with TAS. Fortyfive male volunteers between 50 and 75 years were randomly selected from a medical consultation. The study included a TAS determination by ABTS and a nutritional interview where corporal composition was studied through anthropometry and the habitual consumption of nutrients was estimated by means of 24 hour diary and food consumption frequency questionnaire. Statistical analysis was performed by using Pearson or Spearman correlation coefficient (p <0.05). TAS was positively correlated with lycopene consumption (r=0,295; p=0,049), and negatively with red meat intake (r= -0,403; p= 0,007), while intake of other studied antioxidant nutrients did not correlate significantly with TAS. In conclusion, high intake of lycopene and reduced red meat consumption increase TAS.Fil: Messina, Diego. Universidad "Juan Agustín Maza". Facultad de Farmacia y Bioquímica; ArgentinaFil: Pérez Elizalde, Rafael. Universidad "Juan Agustín Maza". Facultad de Farmacia y Bioquímica; ArgentinaFil: Soto, Catalina. Universidad "Juan Agustín Maza". Facultad de Farmacia y Bioquímica; ArgentinaFil: Uvilla, Ana. Universidad "Juan Agustín Maza". Facultad de Farmacia y Bioquímica; ArgentinaFil: López Laur, José Daniel. Universidad "Juan Agustín Maza". Facultad de Farmacia y Bioquímica; ArgentinaFil: López Fontana, Constanza Matilde. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina. Universidad "Juan Agustín Maza". Facultad de Farmacia y Bioquímica; Argentin

Effect of hyperthyroidism on the development of prostate cancer

Introducción: Las Hormonas Tiroideas (HT) son esenciales para el desarrollo,maduración y metabolismo de todos los tejidos del organismo,por lo que se ha postulado que podrían estar relacionadas también conel crecimiento tumoral. En estudios preclínicos, niveles alterados de HTse han relacionado con un mayor riesgo de desarrollar distintos tipos decáncer; entre ellos, el Cáncer de Próstata (CaP).Objetivo: Analizar artículos epidemiológicos, en donde se estudie la relacióndel hipertiroidismo y el CaP, publicados hasta el momento.Material y Método: Se buscó en plataformas de bases de datos, comoScopus, Mendeley, Science Direct y PubMed. Se filtró por los términoshipertiroidismo y cáncer de próstata, hormonas tiroideas y cáncer depróstata, y hormonas tiroideas y cáncer. Luego, fueron seleccionadosúnicamente los trabajos en humanos.Resultados: Se encontraron 5 estudios epidemiológicos que analizan larelación entre las HT y el CaP; 2 de ellos fueron trabajos retrospectivos,y el resto, prospectivos. Los estudios retrospectivos mostraron nivelesmás elevados de triyodotironina sérica (T3) en pacientes con hiperplasiaprostática benigna y en aquellos con mayor riesgo de recurrencia de CaP,comparados con los controles. Los estudios prospectivos demostraronuna relación inversa entre los niveles de TSH (hormona estimulante de latiroides) y el riesgo de desarrollar CaP, y una correlación positiva entre latiroxina (T4) y el riesgo de CaP.Conclusión: Se ha evidenciado un aumento del riesgo de CaP en personashipertiroideas o con hipertiroidismo iatrogénico resultado de tratamientoscon dosis inadecuadas de levotiroxina.Introduction: Thyroid hormones are essential for the development, maturation and metabolism of all human tissues; therefore, it has been postulated that they could also be associated with tumor growth. Preclinical studies have found a relationship between altered levels of thyroid hormones with increased risk of developing different types of cancer, including prostate cancer. Objective: To analyze epidemiological articles where the relationship of hyperthyroidism and PCa is studied. Material and Method: we searched in database platforms including Scopus, Mendeley, Science Direct and PUBMED. We used key terms like hyperthyroidism and prostate cancer; thyroid hormones and prostate cancer; thyroid hormones and cancer. Then, we selected only those studies that were performed in humans. Results: we found 5 epidemiological studies that investigated the relationship between thyroid hormones and prostate cancer, 2 of them were retrospective and the rest prospective. In the retrospective studies, the authors found higher levels of serum triiodothyronine (T3) in patients with benign prostatic hyperplasia and in those with higher risk of prostate cancer recurrence. In the prospective studies, they observed an inverse relationship between TSH (Thyroid-Stimulating Hormone) circulating levels and the risk of prostate cancer, and a positive relationship between tiroxine (T4) serum levels and prostate cancer. Conclusion: it has been demonstrated an increased risk of prostate cancer in hyperthyroid participants or with iatrogenic hyperthyroidism due to treatment with inadequate doses of levothyroxine.Fil: Rey Echalecu, Lara Sofía. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Cano, Rocio Yasmin. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: López Fontana, Gastón. Universidad Nacional de Cuyo; ArgentinaFil: López Laur, José Daniel. Universidad Nacional de Cuyo; ArgentinaFil: Caron, Ruben Walter. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: López Fontana, Constanza Matilde. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentin

Regulation of prolactin secretion during the estrus in rats: Possible role of glucocorticoids

Mifepristone (MIF) administration to cycling rats at proestrus induces hypersecretion of prolactin (PRL) at the following estrus.We aimed to assess whether this effect is due to the antiprogesterone or antiglucocorticoid action of MIF and to help underscore the nature of the circulating hormone(s) regulating PRL secretion at estrus. Female cycling rats in proestrus were treated with vehicle; the progesterone (Pg) and glucocorticoid receptor antagonists, MIF (5 mg/kg) or ORG-33628 (5 mg/kg); the glucocorticoid agonist dexamethasone (DEX; 27 mg/kg) ± MIF; or the inhibitor of steroid synthesis aminoglutethimide (AG; 150 mg/kg) ± MIF. The animals' blood was sampled the same day at 1800 h and at 1800 h of the following day to assess for circulating PRL and Pg levels. To distinguish antiglucocorticoid from antiprogesterone effects of MIF, we administered a highly specific neutralizing antibody against Pg. None of the antagonists modified serum PRL values at proestrus but increased PRL levels at estrus. DEX decreased the secretion of PRL at proestrus, yet the effect was entirely blocked by MIF. Furthermore, DEX decreased PRL at estrus in a MIF-reversible manner, suggesting that adrenal corticoids during proestrous may regulate PRL secretion at estrus. AG increased PRL secretion at estrus, whereas its association with MIF produced an even higher response. PRL concentration at estrus was not modified by the antiprogesterone antibody, suggesting that the effect of MIF is a consequence of its antiglucocorticoid effect and not due to its antiprogesterone properties. In conclusion, PRL secretion in the afternoon of the estrus is most likely regulated by glucocorticoids through an inhibitory action.Fil: López Fontana, Constanza Matilde. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Maselli, María Eugenia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: de Di Nasso, Florencia E. G.. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Telleria, C. M.. Sanford School Of Medicine; Estados UnidosFil: Caron, Ruben Walter. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentin

Changes in prolactin receptor location in prostate tumors

Introduction: Prolactin (PRL) binds its receptor (PRLR) and stimulates cell proliferation, differentiation and survival in prostate cancer (PCa) cell lines via STAT5a, MAPK and AKT. Objective: To evaluate the expression of PRL and PRLR in normal and tumor prostate tissues with different Gleason patterns. Methods: Samples of normal, benign prostatic hyperplasia and PCa with different Gleason patterns were selected from radical prostatectomy. The intensity, location and percentage of stained cells for PRL and PRLR were evaluated by Immunohistochemistry. Co-localization was observed by confocal microscopy. Results: PRL was expressed diffusely and with a mild intensity in the cytoplasm of normal and tumor prostate luminal cells. Its expression only augmented in the Gleason 3 pattern (p 0.0001). The immunostaining intensity and the percentage of positive cells for PRLR did not vary between normal and tumor tissues. However, the location of the PRLR was modified by the tumorigenic process. In non-tumor tissues, PRLR expression was mostly in plasma membrane in the apical zone of epithelial cells. In tumor tissues, it was expressed in intracellular vesicles. The co-localization of PRL and PRLR was demonstrated in normal and tumor tissues suggesting that PRL could be acting in an autocrine and paracrine manner. Conclusion: PRL and its receptor were present in the cytoplasm of the epithelial cells of the normal and tumor prostate gland. In tumor tissues, the change in the location and appearance of cryptic PRLRs that store PRL may keep active the different signaling pathways related to cell proliferation and survival.Fil: López Fontana, Gastón. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas; Argentina. Clinica Andina de Urología; ArgentinaFil: Rey Echalecu, Lara Sofía. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Santiano, Flavia Eliana. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: López Fontana, José Rodrigo. Clinica Andina de Urología; ArgentinaFil: López Laur, José Daniel. Clinica Andina de Urología; ArgentinaFil: Zyla, Leila Ester. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Valdemoros, Paula. Laboratorio de Anatomía Patológica Vega Valdemoros; ArgentinaFil: Guerrero Gimenez, Martin Eduardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Fernandez Muñoz, Juan Manuel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Gomez, Silvina Esther. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Bruna, Flavia Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Guglielmi, Juan Manuel. Clinica Andina de Urología; ArgentinaFil: Caron, Ruben Walter. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: López Fontana, Constanza Matilde. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentin

High Intake of Maternal Milk Prevents the Development of Mammary Cancer in Pups Maintaining Elevated Ingestion of Saturated Fat

Environmental factors in early life have a strong implication on the development of diseases in adult life. Nutritional changes during perinatal life can modify the susceptibility to develop breast carcinoma. In this report, we studied the influence of a diet high in saturated fat in the development of breast cancer, in rats that maintained a differential milk intake during their lactation period. We also analysed the possible mechanisms involved in tumor development. We compared mammary carcinogenesis in Sprague-Dawley adult rats, grown-up in litters of 3 (L3) or 8 (L8) pups per mother during lactation to induce a differential consumption of maternal milk. After weaning all pups were fed with a diet high in saturated fat “HF” (40% of energy from lipids) until adulthood. At 55 days of age, the animals were treated with a single dose of dimethylbenzanthracene to study tumor latency, incidence and progression. Histological and immunohistochemical studies were performed. We observed that animals that maintained high milk intake (L3) had lower mammary cancer incidence than animals that maintained lower milk consumption (L8; P <0.05) when exposed to a HF diet. Tumor latency and rate of tumor growth did not show variations between the groups. However, the mitotic index (P< 0.05) and the expression of CD1 were significantly lower, in tumors of L3 respect to L8 (P <0.01). Animals with greater consumption of breast milk develop tumors that proliferate less and tend to have a more pronounced apoptotic process, although when maintaining a high consumption of saturated fat. These results may explain, in part, the lower incidence observed in this group of animals. Our work reflects the importance of lactation during postnatal life in the prevention of breast cancer, despite other nutritional factors that may act as promoters of tumor development throughout life, such as the consumption of saturated fat.Fil: Santiano, Flavia Eliana. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Sasso, Corina Verónica. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Zyla, Leila Ester. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Bruna, Flavia Alejandra. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Campo Verde Arbocco, Fiorella. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Pistone Creydt, Virginia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: López Fontana, Constanza Matilde. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Caron, Ruben Walter. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentin

Relación entre los niveles plasmáticos de selenio y las diferentes enfermedades prostáticas

Several studies have demonstrated an inverse relation between serum selenium levels (Se) and advanced prostate cancer (PCa). Objective: To determine and compare selenium plasma levels in patients with different prostatic pathologies. Material and methods: It is a transversal, descriptive and comparative study. A sample of 64 men between 50 and 80 years old were selected for the study between 2007 and 2009. All volunteers underwent a digital rectal examination, prostate specific antigen level, ultrasound and transrectal prostate biopsy (1214 chips). Prostate cancer was subclassified according to Gleason Score. Selenium was determined indirectly by serum Glutathione peroxidase (Kit Ransel, Randox SRL, Crumlin, UK). Statistical analysis was performed using ANOVA I (p<0.05). Results: Glutathione Peroxidase level was 33.75±2.36 mg/ml in control patients. A decrease of 31.6% was observed in patients with BPH (23.08±1.57 mg/ml) and of (63.6%) in subjects with prostate cancer (12.28±1.03 mg/ml) (p<0,0001). There was no correlation with the Gleason Score. Conclusion: Serum Seleniun is lower in patients with prostatic pathologies being even more important in cancer patients regardless the Gleason Score.Fil: López Fontana, Constanza Matilde. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina. Universidad "Juan Agustín Maza". Facultad de Farmacia y Bioquímica; ArgentinaFil: Pérez Elizalde, R. F.. Universidad "Juan Agustín Maza". Facultad de Farmacia y Bioquímica; ArgentinaFil: Vanrell, M. C. M.. Universidad "Juan Agustín Maza". Facultad de Farmacia y Bioquímica; ArgentinaFil: Recalde, Gabriela María. Universidad "Juan Agustín Maza". Facultad de Farmacia y Bioquímica; ArgentinaFil: Uvilla, A. L.. Universidad "Juan Agustín Maza". Facultad de Farmacia y Bioquímica; ArgentinaFil: López Laur, J. D.. Universidad "Juan Agustín Maza". Facultad de Farmacia y Bioquímica; Argentina. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas; Argentin

Estradiol and progesterone regulate proliferation and apoptosis in colon cancer

Epidemiological studies describe estrogens as protectors in the development of colon cancer in postmenopausal women treated with hormone replacement therapy. However, the role of progesterone in colon cancer has been minimally studied and the results are controversial. For the above, the objective of this work was to determine the hormonal regulation exerted by natural ovarian steroids on proliferation and apoptosis in an experimental model of colon cancer in ovariectomized rats treated with 17-beta estradiol and progesterone. Sprague–Dawley rats were exposed to the carcinogen 1,2-dimethylhydrazine to induce colon tumors. Thirty days later, the rats were ovariectomized and treated with estradiol (60 μg/kg), progesterone (10 mg/kg), estradiol plus progesterone (60 μg/kg and 10 mg/kg) or vehicle. We observed no significant differences in colon cancer incidence and tumor multiplicity between the groups. Nevertheless, we observed a decrease in PCNA expression and a greater number of apoptotic index, higher expression of caspase 3, cleaved PARP and cleaved caspase 8 in tumors, confirming the activation of the extrinsic pathway of apoptosis by the combined treatment. In addition, we observed a higher expression of estrogen receptor beta in these tumors. We conclude that the action of both hormones, estradiol and progesterone, is necessary to reduce proliferation and increase apoptosis in colon tumors, probably through estrogen receptor beta activation.Fil: Sasso, Corina Verónica. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Santiano, Flavia Eliana. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Campo Verde Arbocco, Fiorella. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Zyla, Leila Ester. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Semino, Silvana Noemí. Universidad Nacional de Cuyo. Hospital Universitario; ArgentinaFil: Guerrero Gimenez, Martin Eduardo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Pistone Creydt, Virginia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: López Fontana, Constanza Matilde. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Caron, Ruben Walter. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentin